



Wiadomości Lekarskie

Czasopismo Polskiego Towarzystwa Lekarskiego



Pamięci
dra Władysława
Biegańskiego

TOM LXXII, 2019, Nr4, kwiecień

Rok założenia 1928

Wiadomości Lekarskie is abstracted and indexed in: PubMed/Medline, EBSCO, SCOPUS, Index Copernicus, Polish Medical Library (GBL), Polish Ministry of Science and Higher Education.

Copyright: © ALUNA Publishing.

Articles published on-line and available in open access are published under Creative Commons Attribution-Non Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

Zasady prenumeraty miesięcznika Wiadomości Lekarskie na rok 2019

Zamówienia na prenumeratę przyjmuje Wydawnictwo Aluna:

– e-mailem: prenumerata@wydawnictwo-aluna.pl
– listownie na adres:

Wydawnictwo Aluna
ul. Z.M. Przesmyckiego 29, 05-510 Konstancin-Jeziorna

Prosimy o dokonywanie wpłat na numer rachunku Wydawnictwa:
Credit Agricole Bank Polska S. A.: 82 1940 1076 3010 7407 0000 0000

Cena prenumeraty dwunastu kolejnych numerów: 240 zł/rok (w tym 5% VAT)

Cena prenumeraty zagranicznej: 120 euro/rok.
Cena pojedynczego numeru – 30 zł (w tym 5% VAT) + koszt przesyłki.
Przed dokonaniem wpłaty prosimy o złożenie zamówienia.

Victoria S. Sukhan ALLERGIC RHINITIS AND ASTHMA CO-MORBIDITY	622
Oleksandr V. Likunov, Nataliya R. Prisyazhna, Andriy V. Ratushnyuk, Pavlo I. Nikulnikov IMPROVEMENT OF THE METHODS OF SURGICAL TREATMENT IN PATIENTS WITH INFRALENALE ANEURYSM OF THE ABDOMINAL AORTA	627
Sergii D. Khimich, Orest M. Chemerys ROLE OF THE FAMILY PHYSICIAN IN THE TREATMENT OF PATIENTS WITH POLYTRAUMA ON THE OBESITY BACKGROUND ON AN AMBULATORY STAGE	631
Natalia V. Zhovanyk, Mariana I. Tovt-Korshynska INTERACTION BETWEEN CLINICAL AND PSYCHOLOGICAL CHANGES AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PULMONARY TUBERCULOSIS CO-MORBIDITY	635
Sergiy I. Ivashchuk, Larysa P. Sydoruk THE PARAMETERS OF LIVER FUNCTIONAL STATE AS A RISK FACTOR OF EDEMATOUS PANCREATITIS DEVELOPMENT PROVIDING OF GENETIC DETERMINATION OF IL-4 PRODUCTION	639
Khrystyna B. Kvit, Natalya V. Kharchenko, Vyacheslav V. Kharchenko, Olga I. Chornenka, Romania I. Chornovus, Uljana S. Dorofeeva, Oksana B. Draganchuk, Oksana M. Slaba THE ROLE OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN THE PATHOGENESIS OF HYPERLIPIDEMIA	645
Snizhana V. Feysa, Ivan V. Chopei COMORBIDITY SEVERITY INDEX AS A NEW TOOL FOR ASSESSMENT OF CO-EXISTING DISEASES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AT THE CARBOHYDRATE METABOLISM DISORDER BACKGROUND AND CONCOMITANT SUBCLINICAL HYPOTHYROIDISM	650
Oksana V. Bakun, Oksana I. Yurkiv, Ksenia V. Slobodian, Oksana V. Kolesnik, Aliona V. Maruschak THE LEVEL OF SOME HORMONES IN THE BLOOD WOMEN WITH ENDOMETRIOSIS WHICH ASSOCIATED WITH INFERTILITY	654
Valentyna I. Velichko, Yana I. Bazhora, Galyna O. Danilchuk, Larysa I. Kolotvina PSYCHOEMOTIC FEATURES, STATUS OF COGNITIVE FUNCTIONS AND ASSESSMENT OF BRONCHIAL ASTHMA PATIENTS' QUALITY OF LIFE	657
Oleksandr Bredun, Oleg Melnikov, Oleksandr Kononov INTEGRAL SCORING SCALE AS A BASIS FOR AN OBJECTIVE ASSESSMENT OF THE STATE OF PATIENTS WITH CHRONIC TONSILLITIS AND THE EFFECTIVENESS OF THEIR TREATMENT	664
Natalia Y. Osovskaya, Yulia V. Mazur, Olga M. Bereziuk, Serhii P. Dmytrishyn, Maryna M. Velychkovych, Larysa A. Perebetiuk, Olena V. Temna, Oksana M. Honcharenko, Oksana V. Furman, Oleksiy R. Balatskyi CARDIOVASCULAR REMODELING IN PATIENTS WITH HYPERTENSION WITH DIFFERENT DEGREES OF COGNITIVE IMPAIRMENT	670
Iryna V. Chekhovska, Olha M. Balynska, Roman I. Blahuta, Valeriy V. Sereda, Serhii O. Mosondz EUTHANASIA OR PALLIATIVE CARE: LEGAL PRINCIPLES OF THE IMPLEMENTATION IN THE CONTEXT OF THE REALIZATION OF HUMAN RIGHTS TO LIFE	677
PRACE POGLĄDOWE / REVIEW ARTICLES	
Volodymyr O. Shaprynskyi, Oleg Y. Kanikovskiy, Yevhen V. Shaprynskyi, Yaroslav V. Karyi EXPERIENCE IN TREATMENT OF PATIENTS WITH ESOPHAGEAL ACHALASIA	682
Borys O. Lohvynenko, Roman V. Myroniuk, Olexander P. Svitlychnyy, Aleksey Y. Prokopenko, Lidija I. Kalenichenko THE WAY THE HEALTH CARE SYSTEM IN UKRAINE LOOKS LIKE: INTERNATIONAL PRACTICES WITHIN NATIONAL REALITIES	685
Tetyana B. Vilchik, Hrihorii S. Krainyk, Oleksandr O. Shandula LEGAL ENFORCEMENT AND DEVELOPMENT DIRECTIONS OF HEALTH LAW IN UKRAINE	692
Natalia V. Nikitchenko, Andrii M. Khankevych, Dmytro V. Slynko, Tetiana I. Savchuk, Viktor V. Lazariev A MEDICAL ERROR: DOES LAW HELP OR HINDER	697
Natalia Y. Lemish MODERN METHODS OF GREAT OBSTETRICAL SYNDROMES PROGNOSTICATION (LITERATURE REVIEW)	702
Nadiia V. Shulzhenko LEGAL BASES FOR IMPROVING LEGISLATION ON THE TRANSPLANTATION OF HUMAN ANATOMICAL MATERIALS	707
Vladislav I. Teremetskyi, Serhii V. Knys, Vasyl M. Stratonov, Oleksandr M. Khrantsov, Mykola V. Stashchak ORGANIZATIONAL AND LEGAL DETERMINANTS OF IMPLEMENTING INTERNATIONAL EXPERIENCE IN THE HEALTH CARE SECTOR OF UKRAINE	711
Nadiya B. Kuryltsiv, Kateryna M. Halei THE ROLE OF INTERLEUKINS AND THEIR INHIBITORS IN THE DEVELOPMENT OF AUTOIMMUNE UVEITIS	716
OPIS PRZYPADKU / CASE REPORT	
Ivan P. Katerenchuk, Lidija A. Tkachenko, Tetyana I. Yarmola, Viktoriya V. Talash, Savetik T. Rustamyan, Anna L. Pustovoyt, Oleksandr I. Katerenchuk CHURG-STRAUSS SYNDROME: CLINICAL CASE AND ITS FEATURES	723

PRACA ORYGINALNA
ORIGINAL ARTICLE

ALLERGIC RHINITIS AND ASTHMA CO-MORBIDITY

Victoria S. Sukhan

UZHGOROD NATIONAL UNIVERSITY, UZHGOROD, UKRAINE

ABSTRACT

Introduction: The combination of asthma and allergic rhinitis can affect the mutual encumbrance to which other pathogenetic mechanisms join, which worsen the course of both diseases.

The aim of work is to analyze the features of the genotype and phenotype in patients with a co-morbidity of asthma and allergic rhinitis.

Materials and methods: In order to detect the features of asthma and allergic rhinitis, 115 patients were examined. Patients were divided into two groups: the first included 58 patients with allergic asthma and allergic rhinitis co-morbidity, the second – 57 patients with non-allergic asthma morbidity.

Results: For the group of patients with allergic asthma with concomitant allergic rhinitis, the first manifestation of allergy in childhood is characteristic (allergic rhinitis, hay fever, atopic dermatitis). For this group of patients characterized by a heavy family allergic history. Symptoms of allergic rhinitis aggravate the course of asthma. Characteristic correlation of symptoms of allergic rhinitis with distal obstruction and pronounced lability of bronchi. In these patients, the total increase in IgE and blood eosinophilia, in 1,5 times increased blood histamine and the level of exhaled NO₂ have been increased. Also, asthma control with concomitant allergic rhinitis was significantly worse than in an isolated asthma group ($p < 0.05$).

Conclusion: The obtained data allow to distinguishing the phenotype of patients with asthma and allergic rhinitis co-morbidity.

KEY WORDS: asthma, allergic rhinitis, co-morbidity

Wiad Lek 2019, 72, 4, 622-626

INTRODUCTION

Allergy in the twenty-first century, has become a global problem with significant medical, social and economic losses worldwide. Its prevalence increases with each passing year and becomes signs of a pandemic. Thus, according to the World Allergy Organization (WAO - 2013p.), 150 million Europeans suffer from allergic diseases, and by the beginning of 2025 half of the population in Europe will have one or another allergic disease [1].

Allergic respiratory diseases, asthma and rhinitis, are rightly called the 21st century epidemic and modern age diseases. Although modern medicine offers a variety of preventive and therapeutic strategies, the prevalence of these diseases has been dramatically increasing in both developed and undeveloped countries across the world, especially in children and young adult. The WAO estimates there are 300 million asthmatics in the world, and 500 million people with the symptoms of rhinitis [1]. Very often, asthma and rhinitis coexist in one patient. Numerous contemporary studies, guided by the concept “one airway – one disease”, have revealed the epidemiological, pathophysiological and clinical correlation of asthma and allergic rhinitis (AR) [2].

The most common chronic allergic diseases in the world today are asthma and allergic rhinitis (AR). According to epidemiological statistics, 44-68% of patients in AR have asthma, and in 76 - 80% of patients with asthma have co-morbid AR [2]. There is also a chronological relationship

between AR and asthma, which has been repeatedly confirmed by research. Data from the BAMSE cohort (Sweden, 2012) showed that in children aged 1 year, asthma is associated with rhinitis and / or atopic dermatitis (AD) in 38% of cases, and to 12 years of age, this figure increases to 67% [3]. AR is very often an initial manifestation of systemic allergy in the respiratory tract, and eventually the full allergic cascade starts to reach the lower respiratory tract «in the variant of the allergic march» [2, 3]. Other authors note that in children of early age, AR is often not diagnosed due to frequent respiratory infections [4]. Asthma and AR as nosologies have always been considered in detail: diagnosed and treated in different ways, but recent studies have suggested that upper and lower respiratory tract on upper respiratory tract (URT) and lower respiratory tract (LRT) are a manifestation of a single inflammatory process (the hypothesis of «the only respiratory disease» (united airway disease hypothesis)) [5, 6]. The relationship between AR and asthma has been repeatedly found in scientific publications [7, 8], which confirmed the affinity of the anatomy of the mucous membrane of URT and LRT and the course of pathophysiological processes in them. Inflammation of AR and asthma occurs with the participation of identical triggers, immunocompetent cells, inflammatory mediators. Allergic respiratory syndrome - the phenomenon of allergic rhinitis and reverse broncho-obstruction is considered as a manifestation of the same disease in URT and LRT [9]. There are several mechanisms by which allergic inflam-

mation spreads to LRT: allergic mediators from the nose penetrate the LRT with blood flow or by direct drainage, which leads to inflammation and hyperreactivity of the bronchi; through nasal sinus-bronchial reflexes - that is, stimulation of the receptors of the nose and the sinuses leads to reflex bronchospasm. During the symptoms of AR, the inflow of allergens, cold and dry air through the mouth also increases, which also contributes to bronchospasm [10]. In 15-65%, and according to some data [11], 80% of patients with AR have a typical functional marker of asthma - hyperractivity of the respiratory tract (HRT), where the severity of the course of nasal symptoms is closely correlated with the bronchial caliber and the degree of HRT. In clinical practice, there are frequent cases in which patients with isolated AR show a deterioration in spirometry and/or HRT [12]. It is proved that asthma with AR is characterized by a more pronounced lability of the bronchi due to the bronchodilation reaction to the short-acting β_2 -adrenomimetic agent.

In some studies, the association between the presence of AR and the severity of asthma has been proved [13]. Patients with asthma with concomitant AR often needed unscheduled hospitalizations and higher economic costs for treatment. According to some studies, patients with asthma with comorbid AR had a significantly more inflammatory process than patients without AR. Thus, the level of nitric oxide and eosinophils in blood was 2 times higher, and the level of total serum IgE was significantly higher than in patients without AR [14].

Long-term observational studies have shown that AR often precedes asthma. Thus, according to data from 23 years of observation, patients with AR of asthma developed 3 times more often than in patients without AR, and the ratio of chances of association of AR-asthma after 7 years of observation was 7.1 versus 3.9 in control [11]

In most patients with asthma with concomitant AR (65.7%), the course of asthma is uncontrollable. Significant frequency of cases (81.0%) of subjective underestimation by patients in their state compared with the results of the ACT test [15, 16]

One of the most important aspects of inadequate asthma control is its phenotypic heterogeneity. Clinical phenotypes of asthma are heterogeneous. Their formation depends on genetic and environmental influences and is determined by the interaction of the cellular elements of the respiratory tract and the immune system [17]. Phenotyping takes place in two directions: clinical, pathophysiological, molecular markers [17, 18] and options for response to therapy [17]. This explains a large number of genotypes and phenotypes of asthma. The genotype of asthma is determined by the type of inflammation: eosinophilic, neutrophilic, mixed, non-granulocytic.

THE AIM

The purpose of the work was to analyze the features of the genotype and phenotype in patients with a co-morbidity of bronchial asthma and allergic rhinitis.

MATERIALS AND METHODS

A total of 115 patients with asthma were examined on the basis of the SDC "Rehabilitation" of the Ministry of Health of Ukraine in Uzhhorod. All patients had a thorough allergy history, anamnesis of life and disease. Conducted general clinical and diagnostic examination. The function of external respiration (FER) was investigated using the computer spirograph «Pulmovent-2». To determine the features of the co-morbid flow of asthma from AR, all patients were divided into two groups. To the first (I) group included 58 patients with allergic asthma from AR, to the second (II) - 57 patients with asthma (non-allergic) without AR.

RESULTS

The average age in the group of patients with asthma in AR was 29.2 ± 0.68 years, and in the group of patients with isolated asthma was significantly higher and amounted to 38.2 ± 0.76 years. By gender, both groups were dominated by women. The duration of asthma in both groups was almost the same and was 11.1 ± 1.87 years in the first group and 11.6 ± 1.96 years in the second group. While the age of the debut of asthma varied. Thus, in the first group of patients, the age at which debuted asthma was 18.0 ± 1.43 years versus 26.6 ± 1.66 years - in the second group. Formation of asthma in patients with AR was characterized by the onset of symptoms of AR in (2.5 ± 0.55) years. These data are consistent with the literature data that asthma with AR is formed «in the alternative of an allergic march,» when the onset of the allergic process was AD and / or AR [19].

All patients had a thorough allergy history. In the I group of patients, a high indicator of sensitization to household and pollen allergens was established in 50 (86.2%) patients. In the II group, the indicator was significantly lower and amounted to 36 (63.2%) cases, mainly to household chemicals, sharp odors, food allergens.

With the study of hereditary history in patients with asthma with AR, a variety of manifestations of allergy in the family were detected in 38 (65.5%) cases. Among these patients, the presence of allergic diseases in relatives of the I-II line of mother affinity was detected in 22 (57.9%) patients, from the father - in 15 (39.4%) patients and from both parents in 1 (2.7%) of the patient. In the group of patients with atopic asthma heredity was diagnosed in 24 (42.1%) patients, mainly on the maternal line.

In the I group of patients, AR was more often combined with intermittent and persistent asthma of the lung in 42 (72.4%) cases. In addition, in this group of patients also were diagnosed: in 12 (20.7%) cases of professional asthma and 3 (5.2%) - aspirin asthma. The second group consisted mainly of patients with persistent asthma of the mild and moderate course.

Medicinal allergy in the group of patients with asthma with AR was reported in 14 (24.1%) cases to analgin, aspirin, anesthetics. In the comparison group, drug allergy was detected in 19 (33.3%) cases of ephylline, the antibiotics of the penicillin number.

AR in the I group of patients was divided into seasonal allergic rhinitis (SAR) in 48 (82.8%) cases and year-round allergic rhinitis (YRAR) in 10 (17.2%) cases. The YRAR was characterized by the presence of persistent symptoms. The main reasons were domestic dust, household dust mites, mold allergens, cockroaches and others. The cause of SAR was the seasonal appearance of allergenic particles in the air (pollen of plants, trees). It was sometimes difficult to diagnose SAR or YRAR. Thus, in patients with SAR as a result of the trigger action of several seasonal allergens, symptoms were manifested year-round. In turn, the YRAR was sometimes additionally accompanied by the effects of several seasonal allergens. Regardless of the type of AR, the clinical symptoms of the disease were not discrepancies. AR was manifested by symptoms such as difficult nasal breathing, abundant watery discharge from the nasal cavity (rhinorrhea), itching in the nasal cavity, swollen sneezing.

Clinical symptoms of AR were ranked according to the intensity of manifestations (0 absent, lung-1, average gravity-2, severe-3), with the total number of points deducted in accordance with the International Total Score System – Total Symptoms Score (TSS), as well as using the visual analog scale (VAS). TSS in the group of patients with asthma with AR was 8.75 ± 2.01 and VAS – 6.50 ± 1.05 points.

In the comparison group, non-allergic (vasomotor) rhinitis (NAR) was determined in 11 (19.3%) patients. The NAR clinic was distinct from AR, first of all, in the absence of pruritus in the nasal cavity and an attack-like sneezing. NAR increased when the body position changed.

Among the causes of the first attack of myocardial infarction in the I group of patients dominated contact with pollen and everyday allergens in 52 (89.7%) cases. In the II group of patients, the reasons for the formation of non-allergic asthma were called complications after transmitted pneumonia in 35 (61.4%) patients.

The incidence of asthma in the group of patients with AR was 3.2 ± 0.78 times a year, whereas in the comparison group only 1.8 ± 0.54 times a year. Season of exacerbation of asthma in two groups varied. In group I, 48 (82.8%) patients had asthma exacerbations in the spring and / or autumn, whereas in group II in 50 (87.7%) patients - for the winter and autumn.

All patients were examined for the function of external respiration (FER). The lung of the forced vital capacity of the lungs (FVC) was lowered in the I group of patients in 32 (52.2%) cases, and in the II group - in 38 (66.7%) cases. The obstruction of distal bronchus in the group of patients with asthma with AR was 24 (41.4%) cases and correlated with symptoms of difficult nasal breathing. For the II group of patients, generalized obstruction of the bronchi was characteristic in 27 (47.4%) cases.

The bronchial lability was determined according to the recommendations [20] by assessing their response to metered physical activity and inhalation of short-acting β_2 -adrenomimetic agents (200 μg of salbutamol), followed by the calculation of bronchial lability as a sum of components - the bronchoconstriction index (IBC) and bronchodilation (IBD) Positive considered a sample of

salbutamol with an index of IBD more than 12%. The index of bronchospasm in the group of patients with asthma with AR was $11.7 \pm 1.82\%$, and in the group of patients with atopic asthma - $10.9 \pm 2.01\%$. The dilatation index in the I group of patients was $12.6 \pm 2.11\%$, whereas in the II group - $6.8 \pm 1.90\%$. Thus, the lability index in the first group was $24.3 \pm 2.74\%$ against - $17.7 \pm 3.22\%$ in the second group of patients.

Inflammation of the respiratory tract was determined by general clinical, biochemical and immunological methods. Thus, the titre of total serum IgE in the group of patients with allergic asthma with AR was 19.5 ± 1.31 IU against 8.6 ± 1.13 IU in the comparison group. The level of eosinophils in the peripheral blood was also an order of magnitude higher in Group I compared with the II group of patients and was $9.8 \pm 0.62\%$ and $3.8 \pm 0.44\%$ respectively. Histamine of blood serum in the group of patients with allergic asthma with AR was significantly higher than that in the group of patients with non-allergic asthma and was 2.12 ± 0.05 $\mu\text{mol} / \text{l}$ and 1.44 ± 0.05 $\mu\text{mol} / \text{l}$, respectively ($p < 0.001$). Histaminepsexation was decreased and in the I group it was $13.1 \pm 0.93\%$, whereas in the II group it was at $19.0 \pm 1.19\%$. Cholinesterase activity was decreased in the I group to 20.7 ± 1.94 and in the second group to 13.9 ± 1.43 ($p < 0.05$). Various violations and type of inflammation in the respiratory system correlated with changes in the NO - producing system. Thus, the level of NO₂ in the condensate of exhaled air was 9.64 ± 0.31 $\mu\text{mol} / \text{l}$ in the I group, whereas in the second group it was only 3.20 ± 0.14 $\mu\text{mol} / \text{l}$ ($p < 0.05$).

The level of control of symptoms of asthma was determined by the Asthma Control (ACT) test. Patients were asked to answer 5 questions about asthma during the last 4 weeks. The score from 5 to 25 corresponded to different degrees of asthma control. So, the sum of points up to 20 - indicated the uncontrollability of the course of the disease. In the I group, uncontrolled asthma was in 38 (65.5%) patients, whereas in the second group only 19 (33.3%). In addition, in patients with allergic asthma with AR, more pronounced nocturnal asthma symptoms 43 (74.1%) versus 22 (38.6%) in the non-allergic asthma group were more pronounced. The number of use of β_2 -adrenomimetics per day in group I was significantly higher - 286 inhalations versus 154 in group II, apparently due to symptoms of AR, which worsened the patient's condition, especially at night.

DISCUSSION

Thus, after the conducted studies it can be stated that the comorbidity of allergic asthma with AR has its own peculiarities and this group of patients can be considered as a separate phenotype of asthma [17]. This group of patients is characterized by the first manifestation of allergy in childhood. This, as a rule, is AR and / or AD, which is consistent with the data of literature [2, 3, 4]. For this cohort of patients also characterized by a burdened family allergic anamnesis [21]. The debut of allergic asthma in these patients begins at adolescence or adolescence against

the background of diagnosed AR (pollen allergy), AD «in the variant of an allergic march [4, 19]. Such patients often show sensitization to household and pollen allergens, drug allergy to non-steroidal anti-inflammatory drugs and anesthetics. Among the causes of allergic asthma, contact with household and pollen allergens is prevalent. Characteristic high frequency of exacerbations with seasonality - spring and / or autumn. The comorbidity of the two diseases also requires higher economic costs [13, 21]. Symptoms of AR and asthma interact with one another. And as a result - more often the use of medicines. Also, the correlation of AR symptoms with obstructive distal bronchus is characteristic, the lability of the bronchi is expressed.

Patients with allergic asthma with AR have a more pronounced IgE-dependent type of inflammatory process. Thus, the level of total serum IgE and blood eosinophils has increased by more than 2 times, which is in agreement with the data of other scientists [5, 8, 22], that the clinical symptoms of AR and asthma (nasal congestion and bronchospasm) are caused by IgE - dependent inflammation in response to the action of allergens. For this cohort is also characterized by high levels of histamine, reduced histamine secretion and cholinesterase activity of almost 1.5 times. The level of NO₂ in the condensation of exhaled air in patients with allergic asthma with AR is significantly higher than in patients with non-allergic asthma (2-3 times), which is confirmed by data from other studies [8, 14] and is explained by a significant level of allergy to the organism and manifestation of clinical symptoms of AR .

The presence of patients with allergic asthma in the associated AR affects the severity of asthma and the level of control. Asthma control is significantly worse (2 times) due to nightly, daytime symptoms of AR, which in turn increases the use of fast drugs in 1.9 times [13, 15, 23, 24].

CONCLUSION

All of the above suggests that patients with bronchial asthma with concomitant allergic rhinitis form a separate phenotype of asthma. Understanding the features of the course of asthma where allergic rhinitis initiates and complicates its course, taking into account the features of pathogenesis and functional unity of the respiratory tract allows us to work out the strategy of combined therapy of both diseases, aimed at optimizing the effectiveness, safety and cost savings for the treatment of this group of patients.

REFERENCES

1. Pawankar R. World Allergic Organization (WAO) White Book on Allergy: Update 2013; 239 p.
2. Turner P.J., Kemp A.S. Allergic rhinitis in children. *J. of Pediatrics and Child Health.* 2012; 48: 302 – 310.
3. Ballardini N., Kull I., Lind T. et al. Development and co-morbidity of eczema, asthma and rhinitis to age 12 – data from the BAMSE birth cohort. *Allergy.* 2012; 67: 537 – 544.
4. Sarbacher G.B., Pharm D. BCACP Associate Professor of Pharmacy Practice University of the Incarnate World Feik School of Pharmacy San Antonio. *Tehax US Pharmacst.* 2016; 41 (7): 30 – 34.
5. Feschenko Yu.I., Yashina L.A., Polyanskaya V.I., Ignateva V.I. Kompleksnyy podhod k lecheniyu allergicheskogo rinita i bronhialnoy astmyi [An integrated approach to the treatment of allergic rhinitis and bronchial asthma] *Astma ta alergiya.* 2015; 4: 13 – 21. (In Russian).
6. Antipkin Yu.G., Umanets T.R., Lapshin V.F., Nakonechna A.A., Matveeva S.Yu., Pustovalova O.I. Bronhialna astma, poednana z alergichnim rinitom, u ditey: mistse antigistaminnih preparativ u likuvanni. [Bronchial asthma, associated with allergic rhinitis, in children: place of antihistamines in the treatment.] *Astma ta alergiya.* 2014; 4: 60 – 65. (In Ukrainian).
7. Obimbo E.M., Levin M.E. Allergic rhinitis and asthma – evidence for an association. *Current Allergy & Clinical Immunology.* 2013; 26, N1: 976 – 996.
8. Romanyuk L.I. Allergicheskyy rinit kak komorbidnoe sostoyanie bronhialnoy astmyi. [Allergic rhinitis as a comorbid state of bronchial asthma] *Astma ta alergiya.* 2013; 2: 65 – 65. (In Russian).
9. Bourdin A. Upper airway 1: allergic rhinitis and asthma: united disease through epithelial cells. *Thorax.* 2009; 64: 999 – 1004.
10. Potyazhenko M.M. Optimizatsiya likuvannya alergichnogo rinitu u hvorih na intermituyuchu bronhialnu astmu v ambulatorno – poliklinichnih umovahyu. [Optimization of treatment of allergic rhinitis in patients with intermittent bronchial asthma in ambulatory - polyclinic conditions] *Visnik vdnzu «Ukrayinska Medichna Stomatologichna Akademiya».* 2017; 15, 3(51): 156 – 160. (In Ukrainian).
11. Compalati E. The link between allergic rhinitis and asthma: the united airways disease. *Expert Rev Clin. Immunol.* 2010; 6 (3): 413 – 423.
12. Bezrukov L.O., Garas M.N. Nespetsifichna giperreaktivnist bronhiv u shkolyariv iz atopichnim ta neatopichnim fenotipami bronhialnoy astmi. [Non-specific hyperreactivity of bronchus in schoolchildren with atopic and non-atopic phenotypes of bronchial asthma.] *Astma ta alergiya.* 2015; 1: 13 – 16. (In Ukrainian).
13. Bousquet J. Allergic rhinitis and its impact on asthma. *Achievements in 10 years and needs. J. Allergy Clin. Immunol.* 2012; 130 (5): 1049 – 1062.
14. Groot E., Nijkamp A. Allergic rhinitis is associated with poor asthma control in children with asthma. *Tohorax.* 2012; 67: 582 – 587.
15. Ohta K., Bousquet J., Aizawa H. et al. Prevalence and impact of rhinitis in asthma. SACRA, a cross-sectional nation-wide study in Japan. *Allergy.* 2011; 66: 1287 – 1295.
16. Zabolotnyy d.i., Smagina t.v., Zabrodskaya I.v. Dosvid zastosuvannya levotsetirizinu dlya likuvannya patsientiv iz tsilorichnim alergichnim rinitom. [Experience in the use of levocetirizine for the treatment of patients with year-round allergic rhinitis.] *Apteka galitska.* 2008; 15: 52. (In Ukrainian).
17. Toloh O.S., Rudnitska N.D., Chulovska U.B. Geterogennist bronhialnoy astmi ta vibir terapevtichnoy taktiki. [Heterogeneity of bronchial asthma and the choice of therapeutic tactics.] *Klin. Immunologiya. Alergologiya. Infektologiya.* 2015; 7: 17 – 25 (In Ukrainian).
18. Valovirta E. Managing Co-Morbid Asthma With Allergic Rhinitis: Targeting the One-Airway With Leukotriene Receptor Antagonists. *WAO Journal.* 2012; 5: 210 – 211.
19. Koloskova O.K., Bilik G.A. Schodo pitannya komorbidnosti bronhialnoy astmi y alergichnogo rinitu u shkilknomu vitsi. [Concerning the comorbidity of bronchial asthma and allergic rhinitis at school age] *Scientific journal "sciencerise".* 2015; 10/3 (15): 47 – 51. (In Ukrainian).
20. Standartizatsiya legochnyih bronhialnyih testov. Doklad rabochey gruppyi: «Standartizatsiya testov issledovaniya legochnoy funktsii». [Standardization of pulmonary bronchial tests. Report of the working group: "Standardization of Pulmonary Function Test".] *Ofitsialnyy otchet Evropeyskogo respiratornogo obschestva. Pulmonologiya.* 1993; 2: 96. (In Russian).

21. Sakevich V.D., Shlikova O.Yu., Bobrova N.O., Kaydashev I.P. Poshirenist polimorfniy aleley 2258G/A gena TLR2 ta yih zv'yazok z okremimi imunologichnimi pokaznikami sered hvorih na alergichniy rinit. [Prevalence of polymorphic 2258G/A alleles of the TLR2 gene and their association with individual immunological parameters among patients with allergic rhinitis.] *Astma ta alergiya*. 2013; 3: 51 – 55. (In Ukrainian).
22. Umanets T.R., Lapshin V.Yu., Matveeva S.Yu., Pustovalova O.I. Alergichniy rinit i bronhialna astma u ditey: otsinka effektivnosti levotsetirizinu. [Allergic rhinitis and bronchial asthma in children: evaluation of the effectiveness of levocetirizine.] *Sovremennaya pediatriya*. 2016; 3(75): 85 – 89. (In Ukrainian).
23. Rondon C. Local Allergic rhinitis: concept, clinical manifestations and diagnostic approach. *J. Investig Allergol Clin. Immunol.* 2010; 20 (5): 364 – 371.
24. Global Strategy for Asthma Management and Prevention (GINA) revised 2015. http://www.ginasthma.org/local/uploads/files/GINA_Report_2015.pdf

Conflict of interest:

The Author declare no conflict of interest.

CORRESPONDING AUTHOR

Victoria Sukhan

Uzhhorod National University
Narodna Square, 3, 88000, Uzhhorod, Ukraine
tel: +38506738779
e-mail: viktorija.sukhan@uzhnu.edu.ua

Received: 17.02.2019

Accepted: 05.04.2019

PRACA ORYGINALNA
ORIGINAL ARTICLE

IMPROVEMENT OF THE METHODS OF SURGICAL TREATMENT IN PATIENTS WITH INFRALENAL ANEURYSM OF THE ABDOMINAL AORTA

Oleksandr V. Likunov, Nataliya R. Prsyazhna, Andriy V. Ratushnyuk, Pavlo I. Nikulnikov

NATIONAL INSTITUTE OF SURGERY AND TRANSPLANTATION OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE NAMED AFTER O.O.SHALIMOV, KYIV, UKRAINE

ABSTRACT

Introduction: Nowadays, there is an increase number of patients with abdominal aortic aneurysm. The disease has a constantly progressive nature, the result of which is the rupture of aneurysms and a high mortality rate. However, the technologies of operations are still controversial. Unidentified factors of complications and mortality remain with this pathology.

The aim: to determine the risk factors of complications in patients with the aneurysm of the abdominal aorta

Materials and methods: Analyze data of the examination and treatment results of 117 patients with aneurysm of the abdominal aorta. 58 patients were examined and treated according to advanced methods in a treatment group. The control group consisted of 59 patients who were examined and operated according to standard, generally - accepted methods.

Results: According to our observations after the planned operations, the most common were cardiac complications. Analyzing the frequency of complications depending on the type of surgical intervention, we have not established statistically significant differences. More significant volume of blood loss was observed when performing combined operations and aorto-bifem bypass in comparison with aortic bypass and aorto-biiliac bypass.

Conclusions: Combined operations result in a significantly higher blood loss compared to linear prosthetics. The level of intraoperative blood loss in patients with «large» aneurysms is significantly higher than in patients with «small» and «average» aneurysms.

KEY WORDS: aneurysm of the abdominal aorta, complications, factors of risk

Wiad Lek 2019, 72, 4, 627-630

INTRODUCTION

According to modern definition, aortic aneurysm is a progressive chronic degenerative aortic disease that can affect any part of it with life threatening complications [1].

World health statistics point to a steady increase in the incidence of AAA. Today, this pathology is no longer rare and holds a solid position among other cardiovascular diseases [2,3]. According to the data of modern domestic sources in the East European countries, the frequency of observation of aortic aneurysm is an average of 40 people per 100,000 population [4,5]. The disease has a constantly progressive nature, the result of which is the rupture of aneurysms and a high mortality rate. Gaps occur in 6.3 / 100,000 population and in 35.5 / 100,000 populations over 65 years of age [6].

Over the past decade, a development of vascular surgery has led to optimistic results of planned operations with AAA - the numbers of postoperative lethality do not exceed 5-10% [5]. With a development of complications such as aneurysm rupture, postoperative lethality ranges from 67% to 94% [7].

Despite the half-century history of resection of aneurysm, the technique of performing surgical interventions remains controversial. It includes: performing proximal anastomoses with a brittle wall of the aneurysm; methods

of minimal dissection of aneurysm to avoid intraoperative trauma of major veins; revascularization of the extremities with combined aortic aneurysm with dilation or stenosis of iliac arteries.

A number of authors in their observations pay attention to the dependence of various risk factors for pre- and postoperative complications and mortality [5,7].

THE AIM

The aim - to determine the risk factors of complications in patients with abdominal aortic aneurysm.

MATERIALS AND METHODS

The research is based on data analysis of the examination and treatment results of 117 patients suffering aneurysms of the abdominal aorta who were treated in the department of Major Vessel Surgery of the National Institute of Surgery and Transplantation of the National Academy of Medical Sciences of Ukraine named after O.O.Shalimov from 2008 to 2015. The treatment group, consisting of 58 patients, was examined and treated according to advanced methods. The control group of 59 patients was examined and operated according to standard, generally - accepted methods.